Rodriguez Analiz, Brown Christine, Badie Behnam
Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, Calif.
Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory, City of Hope Beckman Research Institute, Duarte, Calif.
Transl Res. 2017 Sep;187:93-102. doi: 10.1016/j.trsl.2017.07.003. Epub 2017 Jul 15.
Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in the treatment of hematological disease, and its utility for treatment of solid tumors is beginning to unfold. Glioblastoma continues to portend a grim prognosis and immunotherapeutic approaches are being explored as a potential treatment strategy. Identification of appropriate glioma-associated antigens, barriers to cell delivery, and presence of an immunosuppressive microenvironment are factors that make CAR T-cell therapy for glioblastoma particularly challenging. However, insights gained from preclinical studies and ongoing clinical trials indicate that CAR T-cell therapy will continue to evolve and likely become integrated with current therapeutic strategies for malignant glioma.
嵌合抗原受体（CAR）T细胞疗法在血液系统疾病治疗中已显示出巨大前景，其在实体瘤治疗中的应用也开始展现。胶质母细胞瘤的预后仍然严峻，免疫治疗方法正在作为一种潜在的治疗策略进行探索。确定合适的胶质瘤相关抗原、细胞递送障碍以及免疫抑制微环境的存在，这些因素使得CAR T细胞疗法治疗胶质母细胞瘤极具挑战性。然而，临床前研究和正在进行的临床试验所获得的见解表明，CAR T细胞疗法将不断发展，并可能与目前恶性胶质瘤的治疗策略相结合。
